000			nab a22 7a 4500
999			_c17100 _d17100
003			PC17100
005			20221129095641.0
008			221129b xxu||||| |||| 00| 0 eng d
040			_cH120
041			_aeng
100			_91250 _aDelgado Jiménez, Juan Francisco _eCardiología
100			_91210 _aGarcía Reyne, Ana _eMedicina Interna
100			_9236 _aDios Pérez, Santiago de _eCardiología
100			_9162 _aLópez Medrano, Francisco _eEnfermedades Infecciosas
100			_9238 _aJurado Román, Alfonso _eCardiología
100			_9869 _aSan Juan Garrido, Rafael _eMedicina Interna
100			_9163 _aRuiz Cano, María José _eCardiología
100			_91017 _aFolgueira López, María Dolores _eMicrobiología y Parasitología
100			_91237 _aGómez Sánchez, Miguel Ángel _eCardiología
100			_9876 _aAguado García, José María _eEnfermedades Infecciosas
100			_9873 _aLumbreras Bermejo, Carlos _eMedicina Interna
245	0	0	_aInfluence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. _h[artículo]
260			_bThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, _c2015
300			_a34(8):1112-9.
500			_aFormato Vancouver: Delgado JF, Reyne AG, de Dios S, López Medrano F, Jurado A, Juan RS et al. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J Heart Lung Transplant. 2015 Aug;34(8):1112-9.
501			_aPMID: 25940077
504			_aContiene 40 referencias
520			_aBackground: Cardiac allograft vasculopathy (CAV) is a major cause of long-term morbidity and mortality after heart transplantation (HTx), whose relationship with CMV infection is uncertain. This study evaluated the influence of CMV infection in the development of CAV. Methods: We enrolled 166 consecutive HTx recipients who underwent their first transplant from January 1995 to July 2002. All patients received 14 days of intravenous ganciclovir and were prospectively monitored for CMV infection during the first year after HTx. CAV was diagnosed by coronary angiography performed at 1, 5, and 10 years after HTx, following the new criteria of the International Society for Heart and Lung Transplantation. We collected all variables potentially related with the development of CAV. Risk factors were studied using a complementary log-log model. Results: After a median follow-up of 11 years (range, 1-17 years), 72 patients (43%) developed CAV (63.8% CAV(1), 15.2% CAV(2), 20.8% CAV(3)). Symptoms secondary to CAV were present in 32% of these patients, and 8% died because of it. In the regression multivariate analysis, independent variables associated with the development of CAV were donor age (hazard ratio [HR], 1.028; 95% confidence interval [CI], 1.002-1.053; p < 0.028), presence of cellular acute rejection ≥ 2R (HR, 1.764; 95% CI, 1.011-3.078; p < 0.0414), CMV infection (HR, 2.334; 95% CI, 1.043-5.225; p < 0.0354), and not having been treated with a calcium channel blocker (HR, 0.472; 95% CI, 0.275-0.811; p < 0.0055). Conclusions: Standardized angiographic criteria show CMV infection is associated with the development of CAV.
710			_9119 _aServicio de Cardiología
710			_96 _aServicio de Medicina Interna
710			_981 _aServicio de Microbiología y Parasitología
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17100.pdf _ySolicitar documento
942			_2ddc _cART _n0